$27.75−0.18 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Zenas Biopharma (ZBIO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
13 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 80% below its peak, net margin −3777.4%.
The four lines that matter · FY23–FY25
Revenue ($M)▲100.0%
10.0
FY23→FY25CAGR −55.3%/yr
Net income ($M)▼140.6%
−377.7
FY23→FY25CAGR —
Free cash flow ($M)▼43.9%
−172.4
FY23→FY25CAGR —
Diluted EPS▲29.0%
−8.44
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
-3777¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -3777.4% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY23–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6762, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 11,000.0 | 10,000.0 | 5,000.0 | 50,000.0 | ▲100.0% | −55.3% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | — | — |
Research & development | 461,717.0 | 339,735.0 | 139,139.0 | 70,033.0 | ▲144.2% | +120.3% |
Selling, general & admin | 75,685.0 | 53,322.0 | 29,749.0 | 17,114.0 | ▲79.2% | +76.5% |
Total operating expenses | 537,402.0 | 393,057.0 | 168,888.0 | 87,147.0 | ▲132.7% | +112.4% |
Operating incomefeeds ROC rank | −526,402.0 | −383,057.0 | −163,888.0 | −37,147.0 | ▼133.7% | — |
Other income, net | −15,137.0 | 5,241.0 | 7,329.0 | 324.0 | — | — |
Pretax income | −541,539.0 | −377,816.0 | −156,559.0 | −36,823.0 | ▼141.3% | — |
Income tax | 269.0 | −79.0 | 429.0 | 301.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −541,808.0 | −377,737.0 | −156,988.0 | −37,124.0 | ▼140.6% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −10.05 | −8.44 | −11.89 | −24.25 | ▲29.0% | — |
Diluted shares (mn) | 66.15 | 44.73 | 13.20 | 1.53 | ▲238.9% | +440.5% |
| Margins | ||||||
Gross margin | —A | —A | —A | —A | — | — |
Operating margin | −4785.5% | −3830.6% | −3277.8% | −74.3% | ▼552.8pp | −3756.3pp |
Net margin | −4925.5% | −3777.4% | −3139.8% | −74.2% | ▼637.6pp | −3703.1pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-16 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Zenas Biopharma's revenue last fiscal year?
Zenas Biopharma reported revenue of $10.0M in fiscal 2025, up 100.0% from fiscal 2024.
What was Zenas Biopharma's net income?
Zenas Biopharma reported net income of −$377.7M in fiscal 2025, a net margin of −3777.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

